Oncology Associates of Oregon

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Endometrial cancer4 trials
• Myelodysplastic syndromes4 trials
• Acute myeloid leukaemia2 trials
• Multiple myeloma2 trials
• Acute lymphoblastic leukaemia1 trial
• Childhood cancers1 trial
• Chronic lymphocytic leukaemia1 trial
• Chronic myeloid leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Gastric and oesophageal cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• and 2 more

Phase

• Phase 36 trials
• Phase 25 trials
• Phase 1/22 trials
• Phase 2/32 trials
• Phase 11 trial

Status

• Recruiting9 trials
• Completed4 trials
• Active, not recruiting2 trials
• Terminated1 trial

Lead sponsor

• Karyopharm Therapeutics Inc2 trials
• Acrivon Therapeutics1 trial
• Akeso1 trial
• Allogene Therapeutics1 trial
• Eli Lilly and Company1 trial
• and 10 more

Running trials

• Recruiting

  Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

  NCT07520006· Phase 1/2· Nurix Therapeutics, Inc.· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

  Contact: Miho Dougherty (principal investigator)

• Recruiting

  Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

  NCT06465953· Phase 3· Institut de Recherches Internationales Servier· Source

  Contact: Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department

• Recruiting

  Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  NCT06500273· Phase 2· Allogene Therapeutics· Source

  Contact: Jeff Sharman, MD (principal investigator)

• Recruiting

  A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

  NCT06095505· Phase 2· Puma Biotechnology, Inc.· Source

  Contact: Puma Biotechnology, Inc. Clinical Operations Senior Director

• Recruiting

  A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

  NCT06196203· Phase 2· Akeso· Source

  Contact: Luke Fletcher

• Recruiting

  Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

  NCT05972135· Phase 2· SCRI Development Innovations, LLC· Source

  Contact: Sarah Cannon Development Innovations, LLC

• Recruiting

  Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  NCT05797831· Phase 2/3· Kartos Therapeutics, Inc.· Source

  Contact: John Mei

• Active, not recruiting

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source

• Active, not recruiting

  A Study of Rusfertide in Adults With Polycythemia Vera (PV)

  NCT05210790· Phase 3· Protagonist Therapeutics, Inc.· Source

• Recruiting

  A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  NCT04988555· Phase 1/2· Sumitomo Pharma America, Inc.· Source

  Contact: Luke Fletcher, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myelodysplastic syndromes3 recruiting
• Multiple myeloma2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Recruiting

  A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  NCT05548296· Phase 2· Acrivon Therapeutics· Source

  Contact: Mansoor Raza Mirza, MD

• Completed

  Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

  NCT04499924· Phase 2/3· Seagen Inc.· Source

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Ipsen· Source

• Completed

  Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

  NCT03555422· Phase 3· Karyopharm Therapeutics Inc· Source

• Terminated

  A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

  NCT02841540· Phase 1· Hemavant Sciences GmbH· Source